研究阿尔茨海默氏症疾病中的性别差异
Ghadha Ibrahim Fouad1, Hisao Ando2, Gaku Ichihara3
1Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt.
Journal of Alzheimer's disease : JAD
|January 6, 2026
概括
由于荷尔蒙变化,阿尔茨海默氏病 (AD) 主要影响女性. 本综述探讨了AD神经病变发生的性别差异,重点关注性激素和治疗干预措施.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样β斑块,高酸化,氧化应激和神经炎症.
- 阿尔茨海默病在女性中患病率更高,这表明性别因素起着重要作用.
研究的目的:
- 为了研究阿尔茨海默病 (AD) 神经病变的基于性别的差异.
- 检查性激素对阿尔茨海默病发展和认知衰退的影响.
- 审查当前的治疗策略,包括激素替代疗法和雌激素受体β干预.
主要方法:
- 审查现有的关于AD性别差异的文献.
- 对NLRP3炎症酶,Nrf2和APOE在性别依赖的AD中的作用的分析.
- 检查激素对大脑新陈代谢,胰岛素抵抗和星细胞活动的影响.
主要成果:
- 女性激素的停止,就像17β-雌激素的下降一样,加剧了AD病理和神经毒性.
- 性别差异显著影响AD痴呆率和神经病变发生.
- 性激素具有抗老年痴呆活动,影响大脑新陈代谢和神经炎症.
结论:
- 了解性别特异性机制对于开发有针对性的AD疗法至关重要.
- 激素替代和以雌激素受体β为基础的疗法在风险人群中减轻AD的前景.
- 大脑新陈代谢,胰岛素抵抗和天体细胞功能的基于性别的差异是AD病变的关键.
关键词:
17β-雌二醇是17β-雌二醇中的一种.阿尔茨海默氏症的疾病是阿尔茨海默氏症.在NLRP3中,NLRP3是NLRP3中的一个.Nrf2 没有任何问题.亚脂蛋白 E 是一种非脂蛋白 E.性别差异是性别之间的差异.更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.6K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.5K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806